The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
about
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyRomidepsin for the Treatment of Peripheral T-Cell Lymphoma5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatmentClinical Toxicities of Histone Deacetylase Inhibitors.Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.Plitidepsin has a safe cardiac profile: a comprehensive analysis.Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy.Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study.Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.Antiemetic therapy in cancer: an update.Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.Does granisetron eliminate the gag reflex? A crossover, double-blind, placebo-controlled pilot study.Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.Targeting histone deacetylases in T-cell lymphoma.Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting.Bradycardia After Intravenous Ondansetron with Asystole on Rechallenge: A Case Report.Comment: electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists.Effects of Palonosetron on Perioperative Cardiovascular Complications in Patients Undergoing Noncardiac Surgery With General Anesthesia: A Retrospective Cohort Study.Cardiac effects of granisetron in a prospective crossover randomized dose comparison trial.
P2860
Q26783229-D3A8A067-C263-4456-A724-8CB7BD62FC97Q26785732-828C0315-8EFE-4A0E-AC0D-4489D4D603D4Q28269736-69346301-A7ED-4C55-B70F-E9BD219EAA53Q31135325-38BAC38F-3F7E-4C5C-AD6F-2B73F606CD70Q33417976-0DF6F688-63CE-4C6C-A03D-E80879E0838DQ34729026-2930CE61-6ABB-4E02-A485-15644340C86AQ35011413-6818A62E-9D1D-4674-9774-91AF803AE23FQ35091717-15A090E8-3CE1-4DF7-87AE-60DCE36A19F8Q35207599-EA5C747C-7851-471F-A173-4A2F97272E06Q35832144-3C4B258C-D209-4D6C-8620-32441AFE8A80Q35909105-E73F6879-F72B-404D-9F69-DCC933B2157FQ36023863-0558F267-46E3-4433-A6F3-BEB7BDBF97F9Q36064937-42B7BAEB-73CB-4C7F-91BA-20EF0EE9DD94Q36222061-26F7F3AC-E1BD-47BF-8C3D-F0037EA3145FQ36715777-E5E9D452-A38D-4D49-857F-6EDBBFE3A57FQ37143278-01FB93A9-95CC-4681-929E-DCB7547233FBQ37854494-D17A8F25-7F09-44AE-ACE2-C62EA147B983Q38098277-701889AF-66E5-4D76-A328-39E07828065BQ38246665-0111CA25-5592-4378-8399-D7E6A41EF0D5Q38998630-1BE86EEE-D00F-4BE9-A691-7DEC43AE3CFBQ39042372-7B9E70D6-1EBD-48BB-8746-7005C4420B75Q42385437-69E35DFA-425C-4566-B728-CE152491962EQ44692428-66026A15-E122-481C-B289-B3520CB9D3D8Q47734534-AD0A60F9-D4A0-4DD4-A212-7710EFE253D7Q54536541-6F136543-63D7-43DA-B15A-6199B202C1C5
P2860
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The cardiotoxic potential of the 5-HT
@nl
The cardiotoxic potential of t ...... s: is there cause for concern?
@ast
The cardiotoxic potential of t ...... s: is there cause for concern?
@en
type
label
The cardiotoxic potential of the 5-HT
@nl
The cardiotoxic potential of t ...... s: is there cause for concern?
@ast
The cardiotoxic potential of t ...... s: is there cause for concern?
@en
prefLabel
The cardiotoxic potential of the 5-HT
@nl
The cardiotoxic potential of t ...... s: is there cause for concern?
@ast
The cardiotoxic potential of t ...... s: is there cause for concern?
@en
P1433
P1476
The cardiotoxic potential of t ...... s: is there cause for concern?
@en
P2093
Deborah L Keefe
P356
10.1634/THEONCOLOGIST.7-1-65
P577
2002-01-01T00:00:00Z